Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients

Multiple Myeloma (MM)

Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study

Biol Blood Marrow Transplant.

Samaras P, Rütti MF, Seifert B, Bachmann H, Schanz U, Eisenring M, Renner C, Müller AM, Schmidt A, Mischo A, Fuchs I, Bargetzi M, Manz MG, Stupp R, Petrausch U, Stenner-Liewen F

doi: 10.1016/j.bbmt.2017.12.775.

Multiple Myeloma (MM)

Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

J Clin Apher.

Moreb JS, Byrne M, Shugarman I, Zou F, Xiong S, May WS, Norkin M, Hiemenz J, Brown R, Cogle C, Wingard JR, Hsu JW

doi: 10.1002/jca.21556.

Multiple Myeloma (MM)

Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma

Cytotherapy.

Tschan-Plessl A, Kalberer CP, Wieboldt R, Stern M, Siegler U, Wodnar-Filipowicz A, Gerull S, Halter J, Heim D, Tichelli A, Tsakiris DA, Malmberg KJ, Passweg JR, Bottos A

doi: 10.1016/j.jcyt.2020.09.009.

Multiple Myeloma (MM)

Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation

Leuk Lymphoma.

Mürner CM, Stenner-Liewen F, Seifert B, Mueller NJ, Schmidt A, Renner C, Schanz U, Knuth A, Manz MG, Scharl M, Gerber B, Samaras P

doi: 10.1080/

Multiple Myeloma (MM)

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Bone Marrow Transplant.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V

doi: 10.1038/s41409-018-0264-8.

Multiple Myeloma (MM)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Leukemia.

Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H

doi: 10.1038/leu.2017.122.

Multiple Myeloma (MM)

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation

Bone Marrow Transplant.

Pandit A, Leblebjian H, Hammond SP, Laubach JP, Richardson PG, Baden LR, Marty FM, Issa NC

doi: 10.1038/s41409-018-0112-x.

Multiple Myeloma (MM)

Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Semin Oncol Nurs.

Koniarczyk HL, Ferraro C, Miceli T

doi: 10.1016/j.soncn.2017.05.004.

Multiple Myeloma (MM)

Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy - a multicenter report by the Polish Myeloma Study Group

Leuk Lymphoma

Drozd-Sokołowska J, Waszczuk-Gajda A, Biecek P, Kobylińska K, Mańko J, Hus I, Szmigielska-Kapłon A, Nowicki M, Romejko-Jarosińska J, Kozioł M, Sędzimirska M, Sachs W, Mądry K, Boguradzki P, Król M, Hus M, Basak G, Dwilewicz-Trojaczek J

doi: 10.1080/10428194.2021.1950712

Related content

Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study

Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma

Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation

Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Salvage autologous hematopoietic stem cell transplantation for multiple myeloma performed with stem cells procured after previous high dose therapy - a multicenter report by the Polish Myeloma Study Group